Abstract: The phenotype results showed that individual pseudoviruses with four thymidine analog mutations (TAMs).[M41L, T67N, L210W, and T215Y] in combination with various other mutations had different levels of resistance to nucleoside reverse transcriptase inhibitors (NRTIs).
Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.
Result: With NVP, the next two mutations, K219E and T215F, complete the TAM-2 cluster, whereas with EFV, the three TAM-1 mutations (M41L, L210W, and T215Y) appear next, along with the K219E from the TAM-2 pathway.
Discussion: Our analysis offers strong evidence that, in contrast to the mutation patterns published for other subtypes, individuals infected with CRF01_AE and experiencing virologic failure while receiving NVP-based HAART favor TAM-2 resistance pathways (K70R, D67N, T215F, K219Q/E) rather than TAM-1 (M41L, L210W, T215Y), wh
Emerging trends of drug-resistant HIV-1 among drug-treated patients in former blood donors in Hubei, China: a three-year surveillance from 2004 to 2006.
Abstract: Genotypic drug resistance analysis showed significant increases in percentages of patients carrying HIV-1 strains with M41L, T215Y/F, D67N, K103N, G190A/S, Y181C/F or L210W mutations.
Does GSS still maintain relevance on HAART outcome after the introduction of newest active antiretroviral drugs? 48 weeks results.
Abstract: RESULTS: The ddI resistance mutations and their resistance scores based on the derivation set were as follows: M41L (score of 14), T69D (24), D123S (40), T139M (54), I180V (53), M184V (-12), V189I (55), Q207K (37), L210W (25), and T215Y (eight).
Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy.
Result: Mutations associated with resistance to nucleoside analogues (NAMs) were also more frequent among women exposed only to dual-drug PLAT (M41L, 5.0%; D67N, 5.0%; K70R, 10.0; and T215Y, 5.0%) than in those treated with 3 drugs (M41L, 1.1%; D67N, 1.1%; K70R, 1.1%; L210F, 1.1%; K219Q, 1.1%).
Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir.
PMID: 20008905
2010
The Journal of antimicrobial chemotherapy
Result: At baseline, Subject 5 had viral clones containing K103N with or without T215A, or with Y188L resistance mutations, while at VF clones with one or more of the following mutations: M41L, D67N, K70R, M184V, Y188L, T215F or L, and K219E were detected, but K103N and T215A were not.
Table: M41L
Figure: Phylogenetic analysis of plasma HIV variants isolated from a representative subject (Subject 5) whose baseline HIV-1 RNA was 5.34 log10 copies/mL and whose baseline (pre-therapy) population genotype resistance mutations included <
N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations.
Introduction: N348I also increased tenofovir resistance when combined with M41L, L210W and Introduction: M41L and T215Y) and N348I, which may result in reduced in vivo drug efficacy.
Introduction: According to the International AIDS Society-USA drug resistance mutations update, the presence of 3 or more TAMs inclusive of M41L and L210W is expected to give a reduced in vivo response to tenofovir.
Introduction: However, when combined with M41L and T215Y (NL/2AZT), N348I decreased tenofovir susceptibility by 1.7-fold (p=0.014, n=4) compared to WT.
Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine.
HIV mutation literature information.
PMID: 
2011
PloS one
Browser Board
Co-occurred Entities
Filtrator
ViMRT